Spoken Alpha
GERON CORP
Geron Corp develops and commercializes RYTELO (imetelstat), a first-in-class telomerase inhibitor approved to treat transfusion-dependent anemia in lower-risk myelodysplastic syndrome patients who have failed or are ineligible for standard therapies.
GERON CORP is a Healthcare company operating in Biotechnology with a $835.2M market cap.
Most recent reported earnings: Q3 FY2026 (Nov 3, 2026).
21 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GERN.
$ curl https://api.spokenalpha.com/v1/companies/GERNFAQ
Spoken Alpha indexes GERN's earnings call transcripts at https://spokenalpha.com/companies/GERN. Each call links to attributed speakers and parsed analyst Q&A.
GERON CORP (GERN) held its most recent earnings call on 2026-08-05, covering fiscal Q2 2026.
GERON CORP (GERN) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-03 | — | $-0.01 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-08-04 | $-0.02 | $-0.01 | -100.0% | $57.5M | — | — | EODHD |
| Q1 FY2026 | 2026-05-05 | $-0.00 | $-0.02 | +75.5% | $51.8M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $-0.02 | $-0.03 | +24.3% | $48.0M | — | — | EODHD |
| Q3 FY2025 | 2025-11-04 | $-0.03 | $-0.03 | 0.0% | $47.2M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $-0.02 | $-0.03 | +33.3% | $49.0M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-0.03 | $-0.04 | +25.0% | $39.6M | — | — | EODHD |
| Q4 FY2024 | 2025-02-25 | $-0.04 | $-0.05 | +23.3% | $47.5M | — | — | EODHD |
| Q3 FY2024 | 2024-11-06 | $-0.04 | $-0.08 | +50.0% | $28.3M | — | — | EODHD |
| Q2 FY2024 | 2024-08-07 | $-0.10 | $-0.10 | 0.0% | $882.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-01 | $-0.09 | $-0.09 | 0.0% | $304.0K | — | — | EODHD |
| Q4 FY2023 | 2024-02-27 | $-0.09 | $-0.10 | +10.0% | $23.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-01 | $-0.08 | $-0.10 | +20.0% | $164.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.09 | $-0.08 | -12.5% | $29.0K | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-0.07 | $-0.10 | +30.0% | $21.0K | — | — | EODHD |
| Q4 FY2022 | 2023-03-15 | $-0.10 | $-0.12 | +16.7% | $103.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-02 | $-0.10 | $-0.09 | -11.1% | $297.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.07 | $-0.09 | +22.2% | $73.0K | — | — | EODHD |
| Q1 FY2022 | 2022-05-08 | $-0.09 | $-0.10 | +10.0% | $123.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-09 | $-0.10 | $-0.08 | -25.0% | $1.0M | — | — | EODHD |
Source: EODHD. GERN reported actuals as published; sparse fields render as —.